Loading...
Market
When will the first commercial sale of 4DMT's 4D-150 gene therapy for wet-AMD occur?
2
Resolution / Starting Odds
Before June 30, 2025 • 25%
Between July 1, 2025 and September 30, 2025 • 25%
Between October 1, 2025 and December 31, 2025 • 25%
After December 31, 2025 • 25%
4DMT official announcements and sales reports
Story
4D Molecular Announces Positive Results for 4D-150 Wet-AMD Gene Therapy
Sep 18, 2024, 08:08 PM
4D Molecular Therapeutics (4DMT) has announced positive results in the development of a gene therapy for wet age-related macular degeneration (wet-AMD), a leading cause of age-related blindness. The therapy, known as 4D-150, has shown robust and durable clinical activity. Notably, only two out of 71 dosed patients have exhibited signs of ocular inflammation. The company has also outlined the design for its upcoming Phase 3 program, known as 4FRONT, during the 4D-150 Wet AMD Development Day. This progress highlights the ongoing advancements in gene therapy, particularly in treatments for common conditions like wet-AMD.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Q1 2026 • 25%
Q2 2026 • 25%
Q3 2026 • 25%
Q4 2026 or later • 25%
Adaptimmune (Afami-cel) • 25%
Checkpoint Therapeutics (Cosibelimab) • 25%
Mirati Therapeutics (Adagrasib-Cetuximab) • 25%
Other • 25%
United States only • 25%
United States and European Union • 25%
United States, European Union, and Japan • 25%
Other combinations or none • 25%
Yes • 50%
No • 50%
Phase III trial initiation • 25%
FDA accelerated approval • 25%
New interim data release • 25%
Other milestone • 25%
Universal gene therapy • 33%
Mutation-specific gene therapy • 33%
No approval • 34%
Safety warning update • 25%
Clinical trial halt • 25%
No action • 25%
Other action • 25%
Yes • 33%
No • 34%
Top 3 but not best-selling • 33%